Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2014

01.08.2014 | Clinical trial

Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival

verfasst von: Christian B. van der Pol, Mark E. Schweitzer, Gina Di Primio, Marcos L. Sampaio, Ania Kielar, Mark Clemons, Arash Jaberi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to determine if bone metastasis characteristics on axial skeleton MRI are associated with either skeletal-related events (SREs) or survival in breast cancer patients. A retrospective review was performed on 247 breast cancer patients with bone metastases identified on axial skeleton MRI. MRI studies were reviewed for metastases T1 signal, signal uniformity, complete vertebral metastatic marrow replacement, metastases quantity, and distribution. Odds ratio (OR) and hazard ratios (HR) were calculated, with 95 % confidence intervals (95 % CI), to determine association with either future SREs or survival. At the time of analysis, 174 (70 %) patients had developed SREs and 176 (71 %) patients were dead. Features of skeletal metastases associated with SREs included the presence of complete metastatic marrow replacement within any vertebra; OR 2.363 (95 % CI 1.240–4.504, P = 0.0090), and more widely distributed metastases; OR 1.239 (95 % CI 1.070–1.435, P = 0.0040). Features associated with shorter survival included the presence of complete metastatic marrow replacement within any vertebra; HR 1.500 (95 % CI 1.105–2.036, P = 0.0093), and more widely distributed metastases; HR 1.141 (95 % CI 1.047–1.243, P = 0.0027). Metastases T1 signal, signal uniformity, and surprisingly quantity were not associated with SREs or survival. Axial skeleton MRI was able to identify characteristics predictive of future SREs and survival. These characteristics could be used for risk stratification for future trials if prospectively validated.
Literatur
2.
Zurück zum Zitat Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278PubMedCrossRef Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278PubMedCrossRef
3.
Zurück zum Zitat Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ (1992) Human breast cancer: survival from first metastasis. Breast cancer study group. Breast Cancer Res Treat 21:173–180PubMedCrossRef Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ (1992) Human breast cancer: survival from first metastasis. Breast cancer study group. Breast Cancer Res Treat 21:173–180PubMedCrossRef
4.
Zurück zum Zitat Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78PubMedCrossRef Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78PubMedCrossRef
5.
Zurück zum Zitat Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed
6.
Zurück zum Zitat Yeatman TJ (1995) The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Oncol Clin N Am 4:569–589PubMed Yeatman TJ (1995) The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Oncol Clin N Am 4:569–589PubMed
7.
Zurück zum Zitat Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19:e303–e304PubMedCentralPubMed Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19:e303–e304PubMedCentralPubMed
8.
Zurück zum Zitat Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259–268PubMedCentralPubMedCrossRef Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259–268PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29PubMedCentralPubMedCrossRef Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 16:879–889PubMedCrossRef Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 16:879–889PubMedCrossRef
11.
Zurück zum Zitat Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef
12.
Zurück zum Zitat Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123:767–779PubMedCrossRef Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123:767–779PubMedCrossRef
13.
Zurück zum Zitat Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M (2010) Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 18:197–203PubMedCrossRef Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M (2010) Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 18:197–203PubMedCrossRef
14.
Zurück zum Zitat Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201PubMedCrossRef Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201PubMedCrossRef
15.
Zurück zum Zitat DePuy V, Anstrom K, Castel L, Schulman K, Weinfurt K, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876PubMedCrossRef DePuy V, Anstrom K, Castel L, Schulman K, Weinfurt K, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876PubMedCrossRef
16.
Zurück zum Zitat Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef
17.
Zurück zum Zitat Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503PubMedCrossRef Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503PubMedCrossRef
18.
Zurück zum Zitat Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 169:1655–1661PubMedCrossRef Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 169:1655–1661PubMedCrossRef
19.
Zurück zum Zitat Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148PubMedCrossRef Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148PubMedCrossRef
20.
Zurück zum Zitat Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105PubMedCrossRef Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105PubMedCrossRef
21.
Zurück zum Zitat Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMedCrossRef Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMedCrossRef
22.
Zurück zum Zitat Yuh WT, Zachar CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR (1989) Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 172:215–218PubMedCrossRef Yuh WT, Zachar CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR (1989) Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 172:215–218PubMedCrossRef
23.
24.
Zurück zum Zitat Baker LL, Goodman SB, Perkash I, Lane B, Enzmann DR (1990) Benign versus pathologic compression fractures of vertebral bodies: assessment with conventional spin-echo, chemical-shift, and STIR MR imaging. Radiology 174:495–502PubMedCrossRef Baker LL, Goodman SB, Perkash I, Lane B, Enzmann DR (1990) Benign versus pathologic compression fractures of vertebral bodies: assessment with conventional spin-echo, chemical-shift, and STIR MR imaging. Radiology 174:495–502PubMedCrossRef
25.
Zurück zum Zitat Noguchi M, Kikuchi H, Ishibashi M, Noda S (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195–201PubMedCentralPubMedCrossRef Noguchi M, Kikuchi H, Ishibashi M, Noda S (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195–201PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Imbriaco M, Larson SM, Yeung HW et al (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4:1765–1772PubMed Imbriaco M, Larson SM, Yeung HW et al (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4:1765–1772PubMed
27.
Zurück zum Zitat Sabbatini P, Larson SM, Kremer A et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948–957PubMed Sabbatini P, Larson SM, Kremer A et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948–957PubMed
28.
Zurück zum Zitat Loeffler RK, DiSimone RN, Howland WJ (1975) Limitations of bone scanning in clinical oncology. JAMA 234:1228–1232PubMedCrossRef Loeffler RK, DiSimone RN, Howland WJ (1975) Limitations of bone scanning in clinical oncology. JAMA 234:1228–1232PubMedCrossRef
29.
Zurück zum Zitat Brown AL, Middleton G, MacVicar AD, Husband JE (1998) T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 53:493–501PubMedCrossRef Brown AL, Middleton G, MacVicar AD, Husband JE (1998) T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 53:493–501PubMedCrossRef
30.
Zurück zum Zitat Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 23:906–912PubMed Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 23:906–912PubMed
31.
Zurück zum Zitat Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCentralPubMedCrossRef Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Koizumi M, Yoshimoto M, Kasumi F, Ogata E (2003) Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 14:1234–1240PubMedCrossRef Koizumi M, Yoshimoto M, Kasumi F, Ogata E (2003) Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 14:1234–1240PubMedCrossRef
33.
Zurück zum Zitat Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17–24PubMedCrossRef Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17–24PubMedCrossRef
34.
Zurück zum Zitat Grankvist J, Fisker R, Iyer V et al (2012) MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 81:e13–e18PubMedCrossRef Grankvist J, Fisker R, Iyer V et al (2012) MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 81:e13–e18PubMedCrossRef
35.
Zurück zum Zitat Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL Jr, Ma J (2013) Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging 31:669–675PubMedCentralPubMedCrossRef Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL Jr, Ma J (2013) Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging 31:669–675PubMedCentralPubMedCrossRef
Metadaten
Titel
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival
verfasst von
Christian B. van der Pol
Mark E. Schweitzer
Gina Di Primio
Marcos L. Sampaio
Ania Kielar
Mark Clemons
Arash Jaberi
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3046-z

Weitere Artikel der Ausgabe 3/2014

Breast Cancer Research and Treatment 3/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.